Novel Biomarkers in Diabesity
Serum biomarkers are proteins that exist in the blood which can be measured and used as a predictor of disease, diagnosis and prognosis.
They are being actively used in cancer medicine, but to date there has been little application in the diabesity area.
The CFGM aims to find biomarkers for diabesity in the hope of being able to use them to help in the diagnosis of diabetes and predict a person's risk of developing the condition or experiencing complications.
With the commissioning of new high quality proteomics equipment provided by Lotterywest and managed by Proteomics International, the Centre's researchers have the capacity to perform high throughput detection of serum biomarkers in relevant cohorts of clinical patients with diabetes and obesity from several different hospitals across Perth.
Outcomes from other research programs will be integrated into subsequent studies to assess relevance and impact, for example, the effect of a particular diet or the impact of metabolic changes on biomarker levels.
Outcomes:
- Identification of novel biomarkers for diabesity in different subject groups.
- Improved diagnosis, management and prognosis of subjects with diabesity.
- Commercialisation of novel biomarkers in diagnostic test kits, and as potential new drug targets.
Principal Investigator:
- Dr Richard Lipsombe - Proteomics International
